Over 650 drugs shortlisted! National Medical Insurance Administration announced.

On August 12, the National Medical Insurance Administration officially announced the preliminary results of the formal review of the adjustment of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug List, as well as the Commercial Health Insurance Innovative Drug List. A total of over 650 drugs have entered the basic medical insurance list and commercial insurance innovative drug list. Among them, 534 passed the initial review of the basic medical insurance list, and 121 passed the initial review of the commercial insurance innovative drug list. The public review period is from August 12 to 18, during which feedback on drug eligibility criteria and information can be provided by the public.